{"nctId":"NCT01096186","briefTitle":"An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease","startDateStruct":{"date":"2010-03"},"conditions":["Parkinson's Disease"],"count":617,"armGroups":[{"label":"Open Label IPX066","type":"OTHER","interventionNames":["Drug: IPX066 95 mg","Drug: IPX066 145 mg","Drug: IPX066 195 mg","Drug: IPX066 245 mg"]}],"interventions":[{"name":"IPX066 95 mg","otherNames":["CD-LD ER 95 mg"]},{"name":"IPX066 145 mg","otherNames":["CD-LD ER 145 mg"]},{"name":"IPX066 195 mg","otherNames":["CD-LD ER195 mg"]},{"name":"IPX066 245 mg","otherNames":["CD-LD ER 245 mg"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Each subject must meet the following inclusion criteria in order to be enrolled in the study:\n\n  1. Successful completion of studies IPX066-B08-05, IPX066-B08-11, or IPX066-B09-02.\n  2. In the opinion of the Investigator, the Parkinson's disease diagnosis is still valid and the subject remains eligible for LD therapy.\n\nExclusion Criteria:\n\n* Each subject must be free of the following exclusion criteria in order to be enrolled in the study:\n\n  1. Received an investigational medication other than those from an IPX066 trial within 4 weeks prior to the planned start of treatment.\n  2. Anticipates functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) during study participation.\n  3. Received within 4 weeks prior to Baseline Visit or planning to take during study participation: nonselective monoamine oxidase (MAO) inhibitors (with the exception of rasagiline).\n  4. In the opinion of the Investigator, should not participate in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III","description":"Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at End of Study.\n\nUnified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome.\n\nSubscales II and III were summed:\n\nPart I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":"13.3"}]}]}]},{"type":"SECONDARY","title":"Total UPDRS Parts I-IV","description":"Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living), UPDRS Part III (Motor Examination), and Part IV (Complications of Therapy \\[In the past week\\]) at End of Study. Includes both scoring by a clinician and a historical report of mental functioning, activities of daily living and complications of therapy in the past week obtained by questioning the patient.\n\nUnified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome.\n\nSubscales II and III were summed:\n\nPart I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":"14.67"}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression (PGI)","description":"Satisfaction of IPX066 using Patient Global Impression (PGI) 7-point scale.\n\nPatient Global Impression 0-7 - higher value indicates increased improvement from study start","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"1.16"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":43,"n":617},"commonTop":["Insomnia","Dyskinesia","Fall","Nausea"]}}}